Annual CFO
$104.00 M
+$874.74 M+113.49%
01 December 2023
Summary:
Sinovac Biotech annual cash flow from operations is currently $104.00 million, with the most recent change of +$874.74 million (+113.49%) on 01 December 2023. During the last 3 years, it has fallen by -$375.31 million (-78.30%). SVA annual CFO is now -99.32% below its all-time high of $15.35 billion, reached on 31 December 2021.SVA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
N/A
01 June 2024
Summary:
Sinovac Biotech quarterly cash flow from operations is not available.SVA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
N/A
01 June 2024
Summary:
Sinovac Biotech TTM cash flow from operations is not available.SVA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -78.3% | - | - |
| 5 y5 years | +1209.3% | - | - |
SVA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.3% | +113.5% | ||||
| 5 y | 5 years | -99.3% | +113.5% | ||||
| alltime | all time | -99.3% | +113.5% |
Sinovac Biotech Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $104.00 M(-113.5%) | - | - |
| Dec 2022 | -$770.75 M(-105.0%) | - | - |
| Dec 2021 | $15.35 B(+3103.1%) | - | - |
| Dec 2020 | $479.31 M(+1126.7%) | $481.10 M(+3312.0%) | $479.31 M(+1843.3%) |
| Sept 2020 | - | $14.10 M(+498.5%) | $24.66 M(+11.2%) |
| June 2020 | - | $2.36 M(-112.9%) | $22.17 M(-24.9%) |
| Mar 2020 | - | -$18.24 M(-169.0%) | $29.54 M(-24.4%) |
| Dec 2019 | $39.07 M(+391.9%) | $26.45 M(+127.9%) | $39.07 M(+92.3%) |
| Sept 2019 | - | $11.61 M(+19.4%) | $20.32 M(-7.1%) |
| June 2019 | - | $9.72 M(-211.7%) | $21.86 M(+420.1%) |
| Mar 2019 | - | -$8.70 M(-213.1%) | $4.20 M(-47.1%) |
| Dec 2018 | $7.94 M(-86.7%) | $7.69 M(-41.5%) | $7.94 M(+3090.0%) |
| Sept 2018 | - | $13.15 M(-265.7%) | $249.00 K(-101.9%) |
| June 2018 | - | -$7.94 M(+59.9%) | -$12.90 M(+159.9%) |
| Mar 2018 | - | -$4.96 M(-417.4%) | -$4.96 M(-64.3%) |
| Dec 2017 | $59.76 M(-529.8%) | - | - |
| Dec 2016 | -$13.90 M(-430.1%) | $1.56 M(+1495.9%) | -$13.90 M(+2089.3%) |
| Sept 2016 | - | $98.00 K(-101.6%) | -$635.00 K(-82.3%) |
| June 2016 | - | -$6.02 M(-36.9%) | -$3.58 M(-225.1%) |
| Mar 2016 | - | -$9.54 M(-164.3%) | $2.86 M(-32.0%) |
| Dec 2015 | $4.21 M(-141.6%) | $14.83 M(-620.6%) | $4.21 M(-191.6%) |
| Sept 2015 | - | -$2.85 M(-771.9%) | -$4.60 M(-29.1%) |
| June 2015 | - | $424.00 K(-105.2%) | -$6.49 M(-48.2%) |
| Mar 2015 | - | -$8.20 M(-236.1%) | -$12.52 M(+23.7%) |
| Dec 2014 | -$10.13 M(-281.6%) | $6.02 M(-227.2%) | -$10.13 M(-346.4%) |
| Sept 2014 | - | -$4.74 M(-15.7%) | $4.11 M(+18.5%) |
| June 2014 | - | -$5.62 M(-3.2%) | $3.47 M(-35.1%) |
| Mar 2014 | - | -$5.80 M(-128.6%) | $5.35 M(-4.1%) |
| Dec 2013 | $5.58 M | $20.26 M(-476.7%) | $5.58 M(-185.8%) |
| Sept 2013 | - | -$5.38 M(+44.0%) | -$6.50 M(-11.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | -$3.74 M(-32.9%) | -$7.38 M(-25.9%) |
| Mar 2013 | - | -$5.57 M(-168.0%) | -$9.95 M(-38.8%) |
| Dec 2012 | -$16.25 M(-216.6%) | $8.18 M(-230.7%) | -$16.25 M(+106.8%) |
| Sept 2012 | - | -$6.26 M(-0.8%) | -$7.86 M(<-9900.0%) |
| June 2012 | - | -$6.31 M(-46.8%) | $35.40 K(-99.6%) |
| Mar 2012 | - | -$11.87 M(-171.6%) | $9.76 M(-30.0%) |
| Dec 2011 | $13.94 M(-197.6%) | $16.58 M(+914.3%) | $13.94 M(+52.4%) |
| Sept 2011 | - | $1.63 M(-52.1%) | $9.15 M(-693.8%) |
| June 2011 | - | $3.41 M(-144.4%) | -$1.54 M(-87.0%) |
| Mar 2011 | - | -$7.69 M(-165.2%) | -$11.82 M(-17.2%) |
| Dec 2010 | -$14.28 M(-129.5%) | $11.79 M(-230.2%) | -$14.28 M(-205.1%) |
| Sept 2010 | - | -$9.05 M(+31.8%) | $13.58 M(-54.9%) |
| June 2010 | - | -$6.87 M(-32.3%) | $30.09 M(-33.3%) |
| Mar 2010 | - | -$10.15 M(-125.6%) | $45.10 M(-6.8%) |
| Dec 2009 | $48.41 M(+360.9%) | $39.65 M(+431.7%) | $48.41 M(+154.0%) |
| Sept 2009 | - | $7.46 M(-8.3%) | $19.06 M(+27.8%) |
| June 2009 | - | $8.14 M(-219.1%) | $14.91 M(+193.7%) |
| Mar 2009 | - | -$6.83 M(-166.3%) | $5.08 M(-51.7%) |
| Dec 2008 | $10.50 M(+143.4%) | $10.30 M(+211.4%) | $10.50 M(+4972.3%) |
| Sept 2008 | - | $3.31 M(-294.8%) | $207.10 K(-106.7%) |
| June 2008 | - | -$1.70 M(+21.0%) | -$3.10 M(+121.0%) |
| Mar 2008 | - | -$1.40 M | -$1.40 M |
| Dec 2007 | $4.32 M(-363.9%) | - | - |
| Dec 2006 | -$1.64 M(+4.2%) | - | - |
| Dec 2005 | -$1.57 M(+2.1%) | - | - |
| Dec 2004 | -$1.54 M(-10.8%) | - | - |
| Dec 2003 | -$1.72 M(+2870.9%) | - | - |
| Apr 2002 | -$58.00 K(-88.3%) | - | - |
| Apr 2001 | -$494.80 K(+41.4%) | - | - |
| Apr 2000 | -$349.90 K | - | - |
FAQ
- What is Sinovac Biotech annual cash flow from operations?
- What is the all time high annual CFO for Sinovac Biotech?
- What is the all time high quarterly CFO for Sinovac Biotech?
- What is the all time high TTM CFO for Sinovac Biotech?
What is Sinovac Biotech annual cash flow from operations?
The current annual CFO of SVA is $104.00 M
What is the all time high annual CFO for Sinovac Biotech?
Sinovac Biotech all-time high annual cash flow from operations is $15.35 B
What is the all time high quarterly CFO for Sinovac Biotech?
Sinovac Biotech all-time high quarterly cash flow from operations is $481.10 M
What is the all time high TTM CFO for Sinovac Biotech?
Sinovac Biotech all-time high TTM cash flow from operations is $479.31 M